Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Dominica Health Times.
Press releases published on October 16, 2025
Aveanna Announces Third Quarter 2025 Earnings Release Date and Conference Call
ATLANTA, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its third quarter results before the market open on Thursday, November 6, 2025, to be followed by a …
Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to- …
MADD Canada and NLC Partner to Fight Impaired Driving Among Newfoundland and Labrador Youth
ST. JOHN’S, Newfoundland and Labrador, Oct. 16, 2025 (GLOBE NEWSWIRE) -- A new school year brings a new opportunity to reach young people with life-saving messages. Today, MADD Canada, in partnership with provincial sponsor NLC, will showcase its 2025-2026 …
MADD Canada et son partenaire, la Société des alcools de Terre-Neuve-et-Labrador, s’unissent pour lutter contre la conduite avec capacités affaiblies chez les jeunes de la province
ST. JOHN’S, Terre-Neuve-et-Labrador, 16 oct. 2025 (GLOBE NEWSWIRE) -- Une nouvelle année scolaire apporte une nouvelle occasion de livrer aux jeunes des messages qui peuvent sauver des vies. Aujourd’hui, MADD Canada, en collaboration avec son commanditaire …
RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases
APOLLO BEACH, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. [OTCQB: RTGN] (“RetinalGenix” or the “Company”), a company developing ultra-high-resolution retinal imaging technology, today announced it has engaged Seer, Inc. (Nasdaq: …
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads
Adcytherix Raises EUR 105M Series A to Accelerate Breakthrough Antibody-Drug Conjugate Pipeline with Strategic Focus on Novel Payloads Financing led by Bpifrance with co-leads Kurma Partners, Andera Partners and Angelini Ventures, followed by other …
Adcytherix lève 105 millions d’euros pour accélérer le développement de son portefeuille d‘anticorps conjugués de nouvelle génération intégrant de nouveaux agents cytotoxiques.
Adcytherix lève 105 millions d’euros pour accélérer le développement de son portefeuille d‘anticorps conjugués de nouvelle génération intégrant de nouveaux agents cytotoxiques. Le tour de table est mené par Bpifrance, en collaboration avec Kurma Partners, …
Aicuris Announces Pritelivir Met Primary Endpoint in Immunocompromised Patients with Refractory Herpes Simplex Virus in Phase 3 Pivotal Trial
Pritelivir demonstrated clinically meaningful and highly statistically significant superiority (p=0.0047) in lesion healing up to 28 days of treatment, compared with standard-of-care (SoC) treatments in refractory Herpes Simplex Virus (HSV) infected …
ENT and Allergy Associates, LLP Welcomes Ethan Moritz, MD to Its Offices in Woodbury and Voorhees, NJ
Tarrytown, New York, Oct. 16, 2025 (GLOBE NEWSWIRE) -- ENT and Allergy Associates, LLP (ENTA), the nation’s largest ENT, allergy, and audiology practice, is proud to announce that otolaryngologist Ethan Moritz, MD has joined its team of world-class …
Rakovina Therapeutics to Present New Data Highlighting Novel ATR Inhibitor with CNS Penetration at the AACR-NCI-EORTC International Conference
VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV, FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced that …
Enterome receives FDA Fast Track designation in follicular lymphoma for lead OncoMimics™ immunotherapy EO2463
Covers low tumor burden “watch-and-wait” setting, an unmet medical need Registrational Phase 3 watch-and-wait to start in 2026 EO2463 has broad potential to treat hemato-oncology indications Paris, France – 16 OCTOBER, 2025 Enterome, a clinical-stage …
AdvanCell appoints experienced biotech and pharma leader, Andrew Kay, as Chair of the Board of Directors
Kay was instrumental in driving the successful development and commercialization of Xofigo®, the first and only approved alpha therapy to date SYDNEY, Australia - October 16, 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing …
Kuros Biosciences increases the annual guidance for 2025, The company reports 77% year-over-year increase for the first nine months of 2025
Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences increases the annual guidance for 2025 The company reports 77% year-over-year increase for the first nine months of 2025 Financial …